Exact Sciences Corporation (EXAS) recently enrolled the first patient in its pivotal Multi-Cancer Early Detection (“MCED”) Falcon Registry Real-World Evidence (“RWE”) study. The Texas-based not-for-profit health system, Baylor Scott & White, will serve as the principal site for the study, with Endeavor Health in Chicago set to begin enrolling patients this fall.The multi-site study will register up to 25,000 patients, evaluating the clinical performance, patient and provider experience, and psychological im ...

Hiroshi Watanabe Since I last covered Exact Sciences (NASDAQ:NASDAQ:EXAS) back in August 2021 it is down by around 35%, it is trading at around $58.75 as per the chart below. This thesis aims to show that the recent upside should continue amid volatility. Data by YCharts Three years back, I had a hold position as despite the biotech's DNA-based cancer diagnostics products becoming mainstream, this field involved heavy R&D expenses with competition faced from the likes of Invitae (OTCPK:OTC:NVTAQ). It wa ...

Exact Sciences Corporation’s (EXAS) robust efforts to enhance Cologuard’s growth are poised to help it grow in the upcoming quarters. The company aims to introduce novel solutions that will revolutionize cancer detection and management, as well as boost its growth trajectory. Strong financial stability adds to the positive. Meanwhile, concerns remain over the adverse impact of macroeconomic pressures and intense competitive space.Meanwhile, heavy dependence on the Cologuard test and operating in a highly co ...

Shares of Exact Sciences (EXAS) have gained 23.4% over the past four weeks to close the last trading session at $55.77, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $80.89 indicates a potential upside of 45%.The mean estimate comprises 19 short-term price targets with a standard deviation of $9.28. While the lowest estimate of $66 indicates an 18.3% increase from the current ...

Exact Sciences Corporation EXAS reported better-than-expected second-quarter financial results on Wednesday.Exact Sciences reported quarterly losses of 9 cents per share, which beat the analyst consensus estimate of losses of 32 cents by 71.88%.The company reported quarterly sales of $699.264 million which beat the analyst consensus estimate of $690.003 million. Screening revenue was $532 million, a 15% increase, and Precision Oncology revenue was $168 million, an increase of 6%.Also, the company announced ...

Exact Sciences Corporation (EXAS) reported a net loss of 9 cents per share in second-quarter 2024, narrower than the year-ago loss of 45 cents per share. The figure beat the Zacks Consensus Estimate of a loss of 37 cents per share.Q2 RevenuesConsolidated revenues totaled $699.3 million, up 12.4% on a reported basis and 13% on a core revenue basis. The figure beat the Zacks Consensus Estimate by 1.6%.Segments in DetailScreening revenues, including laboratory service revenues from Cologuard and PreventionGene ...

Exact Sciences (EXAS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 75.68%. A quarter ago, it was expected that this molecular diagnostics company would post a loss of $0.50 per share when it actually produced a loss of $0.50, delivering no surprise.Over the last four quarters, the company ...

Exact Sciences Corporation (NASDAQ:EXAS) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Erik Holznecht - Manager, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Tycho Peterson - Jefferies Andrew Brackman - William Blair Catherine Schulte - Baird Matt Sykes - Goldman Sachs Dan Arias - Stifel Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Dan Brennan - ...

Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Second-quarter 2024 earnings call July 31, 2024 EXACT SCIENCES 1 Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 02-0478229 (State or other jurisdiction of incorporation o ...